文献速递衰弱、肌少症与跌倒认知障碍与谵妄老年慢病共病管理

衰弱或失能养老院居民接种BNT162b2疫苗6个月后的免疫原性:COVID-A研究

Immunogenicity after 6 months of BNT162b2 vaccination in frail or disabled nursing home residents: The COVID-A Study.
PubMed 文献 · J Am Geriatr Soc · 2021-12-17

这项多中心纵向队列研究纳入西班牙两家长期护理机构的127名居民(平均年龄82.7岁),接种两剂BNT162b2后1个月和6个月检测抗体。第二剂后6个月抗体滴度快速下降,中位损失77.6%;仅接种前感染过COVID-19与抗体下降较慢相关,衰弱、失能、认知障碍、共病和年龄与抗体损失程度无关。

要点

  • 养老院居民接种第二剂BNT162b2后6个月内抗体快速下降,中位损失77.6%。
  • 接种前有COVID-19感染史者抗体下降速率显著低于无感染者。
  • 衰弱、失能、认知障碍、共病和年龄与抗体损失程度无关。

核心结论

  • 长期护理机构老年人在第二剂BNT162b2后6个月内抗体快速丢失,仅接种前COVID-19与较慢的抗体下降速率相关。
  • 数据支持在这一脆弱高危人群中接种第三剂疫苗。

研究设计与样本

  • 多中心纵向队列研究,纳入西班牙Albacete两家长期护理机构的127名居民(90名女性、37名男性),平均年龄82.7岁(范围65-99岁),具有不同衰弱和失能特征。
  • 居民按说明书接种两剂BNT162b2,在第二剂后1个月和6个月检测抗体水平,并评估年龄、性别、既往COVID-19史、共病(Charlson指数)、日常生活活动能力(Barthel指数)、衰弱(FRAIL工具)和认知状态。

主要发现

  • 第二剂后1个月和6个月的平均抗体滴度分别为32,145 AU/ml(SD 41,206)和6,182 AU/ml(SD 13,316)。
  • 所有参与者中位抗体滴度损失为77.6%(IQR 23.8%)。
  • 接种前有COVID-19感染者的抗体下降显著低于无SARS-CoV-2感染史者(72.2% vs. 85.3%;p < 0.001)。
  • 每随访日中位滴度下降为0.47%(IQR 0.14%),仅接种前COVID-19与6个月时较低的抗体下降速率相关(HR 0.17;95%CI 0.07-0.41;p < 0.001)。
  • 衰弱、失能、高龄、认知障碍或共病与抗体损失程度无关。

临床怎么用

  • 对长期护理机构中的衰弱或失能老年人,应关注第二剂BNT162b2后6个月内抗体快速下降,考虑按建议接种第三剂。
  • 接种前COVID-19感染史与较慢的抗体下降相关,但不应因此忽略该高危人群的加强免疫。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is incomplete information regarding evolution of antibody titers against SARS-CoV-2 after a two-dose strategy vaccination with BNT162b2 in older adults in long-term care facilities (LTCFs) with frailty, disability, or cognitive impairment. We aimed to determine IgG antibody titer loss in older adults in LTCFs. METHODS: This is a multicenter longitudinal cohort study including 127 residents (90 females and 37 males) with a mean age of 82.7 years (range 65-99) with different frailty and disability profiles in two LTCFs in Albacete, Spain. Residents received two doses of BNT162b2 as per label, and antibody levels were determined 1 and 6 months after the second dose. Age, sex, previous history of coronavirus disease 2019 (COVID-19), comorbidity (Charlson Index), performance in activities of daily living (Barthel Index), frailty (FRAIL instrument), and cognitive status were assessed. RESULTS: The mean antibody titers 1 and 6 months after the second vaccine dose were 32,145 AU/ml (SD 41,206) and 6182 AU/ml (SD 13,316), respectively. Across all participants, the median antibody titer loss measured 77.6% (interquartile range [IQR] 23.8%). Notably, the decline of titers in individuals with pre-vaccination COVID-19 infection was significantly lower than in those without a history of SARS-CoV-2 infection (72.2% vs. 85.3%; p < 0.001). The median titer decrease per follow-up day was 0.47% (IQR 0.14%) and only pre-vaccination COVID-19 was associated with lower rate of antibody decline at 6 months (hazard ratio 0.17; 95% confidence interval 0.07-0.41; p < 0.001). Frailty, disability, older age, cognitive impairment, or comorbidity were not associated with the extent of antibody loss. CONCLUSIONS: Older adults in LTCFs experience a rapid loss of antibodies over the first 6 months after the second dose of BNT162b2 vaccine. Only pre-vaccination COVID-19 is associated with a slower rate of antibody decrease. Our data support immunization with a third dose in this vulnerable, high-risk population.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Salmerón Ríos S, Cortés Zamora EB, Avendaño Céspedes A, et al. Immunogenicity after 6 months of BNT162b2 vaccination in frail or disabled nursing home residents: The COVID-A Study. J Am Geriatr Soc. 2021. PMID: 34894403. doi:10.1111/jgs.17620

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。